Compare SURG & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | LEXX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Canada |
| Employees | 20 | 7 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 16.5M |
| IPO Year | N/A | N/A |
| Metric | SURG | LEXX |
|---|---|---|
| Price | $0.59 | $0.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $1.50 |
| AVG Volume (30 Days) | ★ 146.7K | 118.0K |
| Earning Date | 04-14-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.77 | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.46 |
| 52 Week High | $3.45 | $1.55 |
| Indicator | SURG | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 39.97 |
| Support Level | $0.47 | $0.56 |
| Resistance Level | $0.94 | $0.85 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 61.03 | 35.79 |
Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.